Beijing Scitop Bio-tech Co (300858) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached ¥169.51 million, up 3.77% year-over-year, while net profit attributable to shareholders dropped 39.09% to ¥25.10 million due to increased expenses from new production capacity and slower-than-expected ramp-up.

• The company maintained its leading position in probiotics, expanded domestic and international markets, and saw robust growth in animal and plant microecological products.

• Major investments in R&D and production bases continued, with significant progress in innovation and industry collaboration.

Financial highlights

• Operating income: ¥169.51 million, up 3.77% year-over-year.

• Net profit attributable to shareholders: ¥25.10 million, down 39.09% year-over-year.

• Operating cash flow: ¥10.16 million, down 63.55% year-over-year.

• Gross margin: 47.09%, down 2.15 percentage points year-over-year.

• Basic and diluted EPS: ¥0.10, down 37.5% year-over-year.

Outlook and guidance

• Management expects continued strong demand for probiotics and microecological products, with industry growth driven by health awareness and regulatory support.

• New production capacity is expected to gradually improve profitability as utilization increases.